Shanghai Fosun Pharmaceutical (600196.SH): The registration application for the drug Engliglitazone and Metformin slow-release tablets has been accepted.

13/09/2024

GMT Eight

Shanghai Fosun Pharmaceutical (600196.SH) announced that its holding subsidiary, Jiangsu Wanbang Biochemical Pharmaceutical Group Co., Ltd., has recently had its drug registration application for the sustained-release tablet of Englitazone and Metformin Hydrochloride accepted by the National Medical Products Administration. The drug is intended for the treatment of type 2 diabetes.

Medprin Regenerative Medical Technologies (301033.SZ) subsidiary's three products received EU MDR certification.

Haoyun Technologies (300448.SZ) plans to distribute a cash dividend of 0.15 yuan per share on September 24th, ex-dividend and ex-rights.

Contact: contact@gmteight.com

Shanghai Fosun Pharmaceutical (600196.SH): The registration application for the drug Engliglitazone and Metformin slow-release tablets has been accepted.

RECOMMEND

HK Stock Market Move | KINGDEE INT'L (00268) rose by over 9%, the company's profit is set to be released soon, under the resonance of numerator and denominator, it is expected to welcome a return to the mean.

Ministry of Finance: The total sales of lottery tickets nationwide in August were 54.369 billion yuan, a year-on-year increase of 2.7%.

HK Stock Market Move | Beer stocks continue to rebound in August, with the month-on-month decrease in beer production narrowing. Sales volume is expected to improve in the second half of the year.